HCWB · HCW Biologics Inc.

HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics to address diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence. The company has no approved products and has generated no revenue from product sales. Its lead clinical candidate, HCW9302, is in a Phase 1 trial for alopecia areata, with the first patient dosed in November 2025. Preclinical candidates include HCW11-018b (a T-cell engager) and HCW11-040 (a multi-functional fusion molecule). The company also has two commercial-ready reagents, HCW9206 and HCW9201, for use in CAR-T and NK cell therapy production.

Financially, the company is pre-revenue and has an accumulated deficit of $108.5 million as of December 31, 2025. Cash and cash equivalents were approximately $1.95 million on an actual basis, with a pro forma as-adjusted cash balance of $8.22 million after giving effect to the offering and recent warrant exercises. The company's net tangible book value per share was $0.84 as of December 31, 2025, and after the offering is expected to be $0.49 per share, resulting in immediate dilution of $0.08 per share for new investors.

The offering is structured as a reasonable best efforts placement of up to 13,625,304 shares of common stock (or pre-funded warrants in lieu thereof) at an assumed price of $0.411 per share, for gross proceeds of up to $5.6 million. There is no minimum offering amount, so the company may raise significantly less. Net proceeds are estimated at $5.2 million, to be used for clinical trials (including HCW9302), IND-enabling studies, up to $2.5 million for marketing, approximately $1.1 million for trade payables and litigation settlements, up to $500,000 for consulting, and general corporate purposes.

Key risks include the company's history of losses and negative cash flow, Nasdaq non-compliance (bid price deficiency with a hearing scheduled for May 5, 2026), and the dilutive nature of the offering. The company also faces risks related to clinical trial outcomes, regulatory approvals, and competition. Insider participation in the offering (directors and officers intend to purchase $430,000) may signal confidence but does not mitigate the fundamental risks.

Management is led by founder and CEO Dr. Hing C. Wong, who previously developed Anktiva® (sold to ImmunityBio for $1.0 billion). The CFO, Rebecca Byam, has a background in finance and accounting. The company's competitive position is weak given its early stage and lack of revenue, but its proprietary platforms (TOBI™ and TRBC) could provide differentiation if clinical data prove positive.